Physician profile
Katherine Cameron
NPI 1508076936
$5,378.13
in general payments reported to CMS, 2019-2025
38 companies · $747 in 2025
The $747 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $849 · 2020: $498 · 2021: $1,279 · 2022: $701 · 2023: $786 · 2024: $519 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,909 · Education: $85.05 · Gift: $57.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,909.44 |
| Education | $85.05 |
| Gift | $57.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cipla USA INC. | $910.66 | 2021 | |
| Abbvie INC. | $454.37 | 2019-2025 | Botox |
| Medtronic USA, INC. | $431.28 | 2019-2020 | |
| Astellas Pharma US INC | $421.18 | 2019-2025 | Veozah, Myrbetriq |
| Medtronic, INC. | $414.49 | 2021-2024 | Interstim |
| Boston Scientific Corporation | $367.13 | 2019-2025 | Axonics, General - Erectile Dysfunction, Rezum Generator |
| Sumitomo Pharma America, INC. | $352.40 | 2023-2025 | Gemtesa |
| Urovant Sciences INC | $275.93 | 2021-2022 | |
| Pfizer INC. | $243.93 | 2019-2024 | |
| Amgen INC. | $236.48 | 2019-2020 | |
| Axonics, INC. | $193.53 | 2021-2024 | Axonics, Bulkamid |
| Caldera Medical, INC | $154.62 | 2021-2025 | Desara |
| Bluewind Medical | $130.12 | 2024 | Revi |
| Allergan, INC. | $97.58 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $87.60 | 2019 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $63.92 | 2021-2022 | |
| Zyla Life Sciences, INC. | $50.74 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $47.79 | 2019 | |
| Ambu INC. | $47.21 | 2022 | |
| Lundbeck LLC | $46.59 | 2025 | Vyepti |
| Laborie Medical Technologies Corp. | $44.78 | 2025 | |
| C. R. Bard, INC. & Subsidiaries | $36.64 | 2022 | |
| Baxter Healthcare | $27.22 | 2025 | Perclot |
| Blue Earth Diagnostics | $26.61 | 2022 | |
| Millicent US INC | $23.65 | 2025 | Intrarosa |
| Mayne Pharma Commercial LLC | $22.66 | 2025 | |
| Novo Nordisk INC | $19.80 | 2025 | Wegovy |
| Organon LLC | $18.76 | 2025 | Nexplanon |
| E.R. Squibb & Sons, L.L.C. | $18.03 | 2021 | |
| Therapeuticsmd, INC. | $15.71 | 2019 | |
| Neotract INC. | $14.90 | 2019 | |
| Hologic Sales and Service, LLC | $14.82 | 2025 | Aptima, Thinprep 2000 Processor |
| Shield Therapeutics INC | $14.68 | 2025 | |
| Duchesnay USA Incorporated | $14.57 | 2019 | |
| Olympus America INC. | $13.77 | 2019 | |
| Merck Sharp & Dohme LLC | $12.96 | 2021 | |
| Amag Pharmaceuticals, INC. | $11.02 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Cameron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.